Caboxen is presented on this website as a cabozantinib medicine in 20 mg and 80 mg strengths. Cabozantinib is a prescription anticancer medicine belonging to a group of drugs known as tyrosine kinase inhibitors (TKIs). It works by blocking certain proteins involved in cancer-cell signaling, tumor growth, and the development of blood vessels that supply tumors.
This website provides educational information about Caboxen and its active ingredient, cabozantinib. Visitors can learn about the medicine’s general purpose, mechanism of action, medical uses, administration considerations, potential side effects, precautions, and product-verification requirements.
Cabozantinib is used in the treatment of certain types of cancer under specific clinical and regulatory conditions. Its approved uses vary according to the dosage form, country, treatment setting, and applicable prescribing information. It is not suitable for every cancer or every patient.
Caboxen is a prescription medicine and should only be used under the supervision of a qualified healthcare professional.
Cabozantinib is an oral targeted anticancer medicine. It is classified as a multi-target receptor tyrosine kinase inhibitor. Rather than acting as a conventional chemotherapy drug, it blocks selected signaling pathways that contribute to cancer development and progression.
Some of the important molecular targets affected by cabozantinib include:
MET
VEGF receptors
AXL
RET
KIT
Other receptor tyrosine kinases involved in cellular signaling
These proteins can contribute to tumor-cell growth, survival, migration, invasion, and the formation of new blood vessels. By inhibiting several of these pathways, cabozantinib can interfere with processes that support cancer progression.
The response to treatment varies between individuals. The medicine does not guarantee tumor shrinkage or a cure, and its benefits must be evaluated by the treating oncology team.
This website identifies Caboxen in two strengths:
Caboxen 20 mg
Caboxen 80 mg
Strength describes the amount of active ingredient contained in an individual dosage unit. It does not establish the correct daily dose for a patient.
The exact dosage form and product-specific manufacturing details for Caboxen require confirmation from its packaging and official product documentation. This distinction is particularly important for cabozantinib because different reference formulations have different strengths, administration instructions, and approved uses.
For example, cabozantinib capsules and tablets are not interchangeable. Their dosing and food-related instructions differ. Patients should never substitute one formulation for another or change a prescribed dose based only on the strength printed on a package.
Cabozantinib has established uses in certain cancer-treatment settings. Depending on the formulation and applicable regulatory approval, these include:
Advanced renal cell carcinoma (RCC), a type of kidney cancer.
Hepatocellular carcinoma (HCC), a common form of primary liver cancer, in specified treatment settings.
Certain differentiated thyroid cancers that meet defined treatment criteria.
Certain advanced, previously treated well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Medullary thyroid cancer for the specific cabozantinib capsule formulation under its applicable approval.
These indications should not be treated as interchangeable. The approved indication for a particular cabozantinib product depends on its formulation, country, and prescribing information. A healthcare professional must determine whether a specific product is appropriate for a particular diagnosis.
Cancer cells can use abnormal signaling pathways to grow, survive, spread, and interact with surrounding tissues. Tumors may also stimulate the development of new blood vessels to obtain oxygen and nutrients.
Cabozantinib inhibits selected receptor tyrosine kinases involved in these processes.
One important target is VEGFR, which participates in signaling associated with blood-vessel formation. Cabozantinib also inhibits MET and AXL, proteins associated with tumor-cell growth, movement, survival, and resistance-related pathways.
By blocking several targets, cabozantinib can interfere with multiple processes involved in cancer progression.
Its mechanism is complex, and the clinical response depends on the cancer type, tumor biology, treatment history, and individual patient factors.
Cabozantinib is generally taken orally, but the correct dose and administration instructions depend on the specific formulation and treatment indication.
The prescribing information for cabozantinib tablets and capsules contains different food-related instructions. For example, the reference tablet formulation is generally taken on an empty stomach, at least one hour before or at least two hours after food. The reference capsule formulation has a different fasting schedule.
These instructions must not be transferred from one formulation to another.
Patients should:
Follow the exact prescription provided by their oncology team.
Confirm whether the medicine is a capsule or tablet.
Take the medicine according to the applicable product instructions.
Avoid changing the dose without medical advice.
Avoid taking an additional dose to compensate for a missed dose unless specifically instructed.
Inform the healthcare team about other medicines, supplements, and herbal products being used.
Cabozantinib can cause serious adverse reactions. Treatment requires medical supervision and appropriate monitoring.
Important safety concerns include:
High blood pressure.
Severe bleeding.
Blood clots.
Gastrointestinal perforation or fistula.
Diarrhea and dehydration.
Hand-foot skin reaction.
Impaired wound healing.
Jaw-bone complications.
Proteinuria.
Liver-related complications.
Pregnancy-related fetal harm.
Patients should contact their healthcare professional promptly if they experience concerning symptoms. Severe abdominal pain, significant bleeding, chest pain, sudden breathing difficulty, severe headache, or sudden neurological symptoms may require urgent medical assessment.
The treating team may recommend monitoring of blood pressure, kidney and liver function, urine protein, electrolytes, and other clinical parameters during treatment.
The Caboxen name and the stated strengths of 20 mg and 80 mg are presented on this website for informational purposes. Product-specific information, including the exact dosage form, manufacturer, marketing authorization holder, country of origin, and regulatory status, should be confirmed using the actual product packaging and appropriate documentation.
No manufacturer identity or regulatory approval should be assumed without reliable evidence.
Patients and healthcare professionals should verify the product before use, particularly when the medicine is obtained through an unfamiliar supply channel.
Cabozantinib may be prescribed for eligible patients with specific cancer diagnoses. Suitability depends on factors such as:
Cancer type and stage.
Previous treatments.
General health and performance status.
Liver and kidney function.
Blood pressure and cardiovascular health.
Risk of bleeding or blood clots.
Other medicines being taken.
Pregnancy status and reproductive considerations.
Only a qualified healthcare professional can determine whether cabozantinib is an appropriate treatment option.
This website aims to provide clear, responsible, and educational information about Caboxen and cabozantinib. It is intended to help visitors understand the medicine and the questions they may wish to discuss with their healthcare professionals.
The information provided does not replace an official prescribing document, a medical consultation, or individualized treatment advice.
Caboxen should only be used when prescribed by an authorized healthcare professional and when the identity and formulation of the product have been appropriately verified.
No posts found.
Cabozantinib has a relatively long elimination half-life, meaning it can remain in the body for an extended period after a dose. Its exposure may be influenced by liver function, other medicines, and individual patient characteristics. Patients should follow their oncologist's instructions regarding treatment interruptions and discontinuation.
Cabozantinib may cause proteinuria, which means an increased amount of protein in the urine. Kidney-related monitoring may include urine protein testing and assessment of kidney function. Patients should report unusual swelling, changes in urine output, or other concerning symptoms.
Cabozantinib treatment may be associated with changes in thyroid function. Healthcare professionals may arrange thyroid-function tests during treatment, particularly when clinically indicated. Patients should report unusual tiredness, unexplained weight changes, or other symptoms that may suggest thyroid problems.
Yes. Changes in taste have been reported with cabozantinib. Some patients may notice that food tastes different or that their appetite decreases. Persistent taste changes or difficulty maintaining adequate nutrition should be discussed with a healthcare professional.
Swelling or fluid retention may occur during cabozantinib treatment. Patients should report new or worsening swelling in the legs, feet, hands, or face. Sudden swelling in one leg, particularly with pain, or swelling accompanied by breathing difficulty requires urgent medical assessment.
Older adults may receive cabozantinib when it is appropriate for their cancer and overall health. The oncologist should consider age-related health conditions, liver and kidney function, other medicines, and treatment tolerance before prescribing it. Close monitoring may be necessary.
Cabozantinib is not routinely suitable for children. Pediatric use depends on specific clinical circumstances, formulation, and applicable regulatory authorization. It should never be given to a child unless prescribed by an appropriately qualified specialist.
Cabozantinib may interfere with normal wound healing and increase the risk of certain surgical complications. Patients should inform their oncologist and surgeon before planned surgery. Treatment may need to be temporarily withheld before and after surgery according to the applicable prescribing information and the patient's recovery.
Yes. Cabozantinib has been associated with osteonecrosis of the jaw, a condition involving damage to jawbone tissue. Patients should maintain good oral hygiene, inform their oncologist about dental problems, and discuss planned tooth extractions or other invasive dental procedures before undergoing them.
Changes in calcium levels have been reported during cabozantinib treatment. Healthcare professionals may monitor blood calcium and other relevant laboratory values when appropriate. Patients should report unusual muscle cramps, tingling, weakness, or other concerning symptoms.
Grapefruit and grapefruit juice may affect CYP3A4 activity, an enzyme involved in cabozantinib metabolism. This could alter medicine exposure. Patients should discuss grapefruit products and dietary supplements with their healthcare professional and follow the applicable product instructions.
Cabozantinib may cause fatigue, dizziness, weakness, or other symptoms that affect concentration and daily activities. Patients should understand how the medicine affects them before driving or operating machinery. Avoid these activities if you feel unwell or unable to perform them safely.
Contact a healthcare professional or seek urgent medical advice if an extra dose is taken. An overdose may increase the risk of serious adverse reactions. Do not wait for symptoms to appear, and do not attempt to compensate by changing future doses without medical guidance.
Some herbal products and dietary supplements may affect medicine metabolism or increase treatment-related risks. Patients should inform their oncologist and pharmacist about every supplement, herbal preparation, vitamin, and nonprescription product they use before combining them with cabozantinib.
Store Caboxen according to the instructions on its verified product packaging. Keep the medicine in its original container, protect it from unsuitable storage conditions, and keep it away from children and pets. Do not use expired medicine or products with damaged or suspicious packaging.